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Abstract: The incidence of inflammatory bowel disease (IBD) increases gradually in Western
countries with high need for novel therapeutic interventions. Mannich curcuminoids, C142 or C150
synthetized in our laboratory, have been tested for anti-inflammatory activity in a rat model of TNBS
(2,4,6-trinitrobenzenesulphonic acid) induced colitis. Treatment with C142 or C150 reduced leukocyte
infiltration to the submucosa and muscular propria of the inflamed gut. C142 or C150 rescued the loss
of body weight and C150 decreased the weight of standard colon preparations proportional with 20%
less tissue oedema. Both C142 and C150 curcumin analogues caused 25% decrease in the severity of
colonic inflammation and haemorrhagic lesion size. Colonic MPO (myeloperoxidase) enzyme activity
as an indicator of intense neutrophil infiltration was 50% decreased either by C142 or C150 Mannich
curcuminoids. Lipopolysaccharide (LPS) co-treatment with Mannich curcuminoids inhibited NF-κB
(nuclear factor kappa B) activity on a concentration-dependent manner in an NF-κB-driven luciferase
expressing reporter cell line. Co-treatment with LPS and curcuminoids, C142 or C150, resulted
in NF-κB inhibition with 3.57 µM or 1.6 µM half maximal effective concentration (EC50) values,
respectively. C150 exerted a profound inhibition of the expression of inflammatory cytokines, tumor
necrosis factor-α (TNF-α), interleukin-6 (IL-6), and interleukin-4 (IL-4) in human PBMCs (peripheral
blood mononuclear cells) upon LPS stimulus. Mannich curcuminoids reported herein possess a
powerful anti-inflammatory activity.
Keywords: curcumin; Mannich curcuminoids; inflammation; colitis; inflammatory bowel disease
1. Introduction
Acute inflammation is an evolutionarily advantageous primary response to infections or tissue
injury. After the recruitment of inflammatory leukocytes and production of inflammatory mediators the
resolution of the inflammation is a pre-requisite for physiological homeostasis. Chronic inflammation
Molecules 2019, 24, 1546; doi:10.3390/molecules24081546 www.mdpi.com/journal/molecules
Molecules 2019, 24, 1546 2 of 14
may be a consequence of a primary disease, like persistent infection, stroke, or heart disease, or the cause
of a secondary disease, like autoimmune diseases, diabetes, Amyotrophic lateral sclerosis, Alzheimer’s
disease, and even depression [1]. Smouldering chronic inflammation may be considered an individual
disease without manifesting symptoms associated with a known disease [2]. Several molecular
mechanisms link chronic inflammation with pathologies. Previously, we thoroughly reviewed
cancer-related inflammation elsewhere [3,4]. The overall discussion of chronic inflammation-related
pathologies is beyond the scope of the current paper. Our current work focuses on the effects of
curcuminoids in ulcerative colitis.
Inflammatory bowel disease (IBD) is a group of chronic inflammatory disorders of the
gastrointestinal tract. Ulcerative colitis (UC) and Crohn’s disease (CD) are the two major subtypes of
IBD. While they share common symptoms—chronic, idiopathic, relapsing, abdominal pain–there are
clinical parameters and epidemiological features that are entirely different [5]. The main differences
between UC and CD is the tissue localization of the disease. While inflammation persists in the
mucosal and submucosal layers of the colon in UC, in cases of CD typically the entire gastrointestinal
tract is affected. Incidence of both UC and CD is growing worldwide, with the highest annual
incidence of UC, 24.3 per 100,000 person/years, and of CD, 12.7 per 100,000 person/years, in Europe [6].
While the pathogenesis of UC is still unknown, numerous theories have been proposed. It was
suggested that interaction of immunological, environmental, and microbial factors contributes to the
manifestation of the disease. We have previously shown the anti-inflammatory effect of physical
exercise; recreation led to reduced area of lesions and decreased expression of Il-1β (interleukin 1 beta),
CXCL1 (C-X-C motif chemokine ligand 1), and MPO in a rat model of colitis [7]. We have also reported
the alleviated mucosal and neuronal damage in recurrent colitis [8] and the development of intestinal
strictures due to high MMP9 (matrix metallopeptidase-9) and lower TIMP1 (TIMP metallopeptidase
inhibitor 1) expression in the colon [9]. In the treatment of UC oral or intravenous steroids, calcineurin
inhibitors (tacrolimus, cyclosporine) anti-inflammatory drugs, compounds containing 5-aminosalicylic
acid, thiopurins and immunomodulators (e.g. tumor necrosis factor (TNF)-α targeting monoclonal
antibodies), are administered [10,11]. Despite novel medical treatments, about 20–30% of UC patients
need surgical intervention eventually [12]. Since the overall cure of UC was unresolved, our attention
turned toward a dietary supplement, namely curcumin with anti-inflammatory behavior, to treat
colonic inflammation [13].
Turmeric spice, curcuma, has been used as a dietary supplement for centuries for its intense yellow
coloration and special taste in addition to its empirical beneficial health effects [14]. Curcuminoids,
active components of turmeric, can be extracted from the rhizomes of Curcuma longa with different
ratios: Dihidroxy-dimetoxycurcumin (curcumin, 75–77%), mono-demethoxycurcumin (17–19%),
and bis-demethoxycurcumin (2–3%) [15]. Clinical trials verified the safety of curcumin intake
without reporting toxicity dosing for up to 8000 mg daily for three months in patients with different
malignancies [16]. Lao et al. treated healthy volunteers with high doses of up to 12000 mg of curcumin
with 30% of the subjects reporting only grade 1 side effects [17]. Regarding the safety of curcumin, the
Food and Drug Administration office of the USA has approved curcumin with a “generally regarded
as safe” GRAS designation [18]. The anti-inflammatory properties of curcumin have been previously
demonstrated [13]; however, its inherent poor bioavailability presents an obstacle for its clinical
application [19]. In an effort to circumvent this problem, we have synthetized analogs of curcumin to
increase their efficacy and pharmacodynamics. Our group previously reported the anticancer effect of
Mannich curcuminoids in lung cancer [20], leukemia [21], pancreas [15], and glioma [22] models. Here,
we demonstrate, for the first time, the potent anti-inflammatory effect of Mannich curcuminoids in an
induced colitis model in a rat.
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2. Results
2.1. Relation of Mannich Substrates to Naturally Occurring Curcuminoids
Recently, a library of a structurally diverse set of 47-membered Mannich curcuminoid was created
via a powerful Mannich-3CR (M-3CR)/Claisen-Schmidt condensation sequence [20]. Utilization
of the Mannich protocol, including the assemblies of aromatic aldehydes, primary amines, and
pentane-2,4-dione, led to the formation of various Mannich structures as valuable intermediates with
two optionally variable diversity points. Their treatment with aromatic aldehydes constituted a
symmetrically substituted heptadienedione back-bone furnishing the desired curcuminoid species
via morpholinium chloroacetate-catalyzed Claisen-Schmidt condensation [20,23]. Sythesis and NMR
(nuclear magnetic resonance) analysis have been published earlier [20]. Here, we focus on the
anti-inflammatory effect of derivatives of naturally occurring curcumin (Figure 1A) two Mannich
curcuminoids C142: N-((E)-5-(3,5-dihydroxyphenyl)-2-((E)-3-(3,5-dihydroxyphenyl)acryloyl)-3-oxo-1-
phenylpent-4-en-1-yl)acetamide and C150: N-((E)-5-(3-hydroxyphenyl)-2-((E)-3-(3-hydroxyphenyl)
acryloyl)-3-oxo-1-phenylpent-4-en-1-yl)acrylamide (Figure 1B).
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Figure 1. (A) Structures of naturally occurring curcuminoids and (B) structures of Mannich
curcuminoids C142: N-((E)-5-(3,5-dihydroxyphenyl)-2-((E)-3-(3,5-dihydroxyphenyl)acryloyl)-3-oxo-1-
phenylpent-4-en-1-yl)acetamide and C150: N-((E)-5-(3-hydroxyphenyl)-2-((E)-3-(3-hydroxyphenyl)
acryloyl)-3-oxo-1-phenylpent-4-en-1 yl)acrylamide.
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2.2. Anti-Inflammatory Effects of Curcumin Analogues in 2,4,6-trinitrobenzenesulphonic acid (TNBS)
Induced Colitis
Colonic administration of 2,4,6-trinitrobenzenesulphonic acid (TNBS) resulted in inflammatory
damage of the colon inspected macroscopically 72 h after the challenge. The occuring macroscopic
damage represented haemorrhagic necrosis due to intense tissue inflammation and hyperaemia
(Figure 2B). Mannich curcuminoids, C142 and C150 (Figure 2C,D, respectively), exerted a protective
effect at comparable degrees to the golden standard therapeutic, TNF-α neutralizing antibody,
Infliximab (Figure 2E). There was no deleterious effect detected in the absolute control (vehicle-treated
non-colitis-induced) group of rats (Figure 2A).
Molecules 2019, 24, x FOR PEER REVIEW 4 of 14 
 
2.2. Anti-Inflammatory Effects of Curcumin Analogues in 2,4,6-trinitrobenzenesulphonic acid (TNBS) 
Induced Colitis 
Colonic administration of 2,4,6-trinitrobenzenesulphonic acid (TNBS) resulted in inflammatory 
damage of the colon inspected macroscopically 72 h after the challenge. The occuring macroscopic 
damage represented haemorrhagic necrosis due to intense tissue inflammation and hyperaemia 
(Figure 2B). Mannich curcuminoids, C142 and C150 (Figure 2C,D, respectively), exerted a protective 
effect at comparable degrees to the golden standard therapeutic, TNF-α neutralizing antibody, 
Infliximab (Figure 2E). There was no deleterious effect detected in the absolute control 
(vehicle-treated non-colitis-induced) group of rats (Figure 2A). 
 
Figure 2. The 2,4,6-trinitrobenzenesulphonic acid (TNBS)-induced colitis developed to a macroscopic 
inflammatory damage in the colon of rats. Experimental groups were as follows: (A) Absolute 
control, (B) TNBS-induced colitis, (C) TNBS + C142, (D) TNBS + C150, and (E) TNBS + Infliximab. 
Representative images of 8 cm long fresh colon preparations after treatments. Colitis was induced as 
described in Section 4.2 in Materials and Methods. 
While healthy lamina propria and submucosa of the absolute control animals contained only 
few leukocytes (Figure 3A), histomorphology of the colon specimens revealed the local 
inflammatory tissue architecture and cellular composition of the rats bearing colitis (Figure 3B). 
Sever colitis represented an enlarged, oedematous submucosa with extended leukocyte infiltration 
even to muscularis propria (Figure 3B). These signs of acute colitis were milder in the treated 
animals by both C142 (Figure 3C), C150 (Figure 3D), or Infliximab (figure 3E) showing reduced 
thickness of the submucosa and lower degrees of lymphoreticular infiltrate. 
Figure 2. The 2,4,6-trinitrobenzenesulphonic acid (TNBS)-induced colitis developed to a macroscopic
inflammatory damage in the colon of rats. Experimental groups were as follows: (A) Absolute
control, (B) TNBS-induced colitis, (C) TNBS + C142, (D) TNBS + C150, and (E) TNBS + Infliximab.
Representative images of 8 cm long fresh colon preparations after treatments. Colitis was induced as
described in Section 4.2 in Materials and Methods.
While healthy lamina propria and submucosa of the absolute control animals contained only few
leukocytes (Figure 3A), histomorphology of the colon specimens revealed the local inflammatory tissue
architecture and cellular composition of the rats bearing colitis (Figure 3B). Sever colitis represented an
enlarged, oedematous submucosa with extended leukocyte infiltration even to muscularis propria
(Figure 3B). These signs of acute colitis were milder in the treated animals by both C142 (Figure 3C),
C150 (Figure 3D), or Infliximab (Figure 3E) showing reduced thickness of the submucosa and lower
degrees of lymphoreticular infiltrate.
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Figure 3. The TNBS-induced colitis developed to local inflammation (tissue oedema and infiltration
of inflammatoy cells, arrowheads) in the colon. Experimental groups were as follows: (A) Absolute
control, (B) TNBS-induced colitis, (C) TNBS + C142, (D) TNBS + C150, and (E) TNBS + Infliximab.
Representative H and E images of colon preparations after treatments as described in Section 4.4 in
Materials and Methods. Scale bar = 100 µm.
Initially, following TNBS treatment, animals showed symptoms of weakness, bloody iarrhea,
and weight loss, while rats in the absolute control group gained weight (Figure 4A). By t e end of
the third day, rats w colitis lost 20% of their body weight, while co trols increased their weight
by 15%. Treatment either by curcuminoids (C142 p < 0.01, C150 p < 0.001) or Infliximab (p < 0.001)
almost preserved the initial body weight of rats bearing colitis (Figure 4A). The weight of the standard
colonic segment upon investigation corresponded to the degree of local colonic oedema [24]. Colonic
instillation of TNBS resulted in four times higher colon weight compared to sham (only vehicle-treated)
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animals (p < 0.001). Similarly to Infliximab, C150, the acrylamid Mannich curcumin derivative inhibited
the colonic oedema, reducing the effect of TNBS by almost 20% (p < 0.01) (Figure 4B).
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Figure 4. (A) Body weight change and (B) colon weight change in TNBS-induced colitis. Treatment
with C142 or C150 rescued the loss of body weight and the degree of tissue oedema in the colon.
Experimental design and treatments are described in Sections 4.2 and 4.3 in Materials and Methods.
Results are shown as mean ± S.E.M.; n = 8–11; * p < 0.05, ** p < 0.01, *** p < 0.001 pair-wise comparison
with TNBS-treated group.
The severity of the colonic destruction was scored on a 0–11 scale in a randomized, blinded fashion
according to Boughton-Smith et al. [25]. Scores dire tly correspond to the extent of inflammatio an
ulceration in the standard col ic segment. Challenge with TNBS result d in an 8.6 ± 0.4 (n = 10)
i fl t ry damag score after 72 h (Figure 5A). Both C142 and C150 decreased the severity of
macroscopic mucosal damage to 6.4 ± 0.56 (p < 0.01) and 7.0 ± 0.33 (p < 0.01), respectively (Figure 5A).
Infliximab had the m t potent anti-infl matory effect, reducing severity to 6.1 ± 0.48 ( . 01)
(Figure 5A). Planimetry was used to quantify the area of macroscopic lesions, the haemorrhagic
and necrotic colonic areas expressed as a % of the total area under investigation. TNBS destructed
64.4 ± 2.98% of the standard colonic area, whil treatments reduced macroscopic colonic damage by an
average 20–25% (C1 2: 50. ± 5.05, p < 0.01; C150: 52.1 ± 4.06, p < 0.05 and Infliximab: 51.8 ± 3.49,
p < 0.05) (Figure 5B).
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Figure 5. (A) Severity scale and (B) lesion size of the inflamed colon preparations. Both C142 and C150
curcumin analogues exerted a significant decrease in the severity of colonic inflammation and lesion
size. Severity scaling and the measurement of lesion size was performed as described in Section 4.5 of
Materials and Methods. Results are shown as mean ± S.E.M.; n = 8–11; * p < 0.05, ** p < 0.01, *** p < 0.001
pair-wise comparison with TNBS-treated group.
Molecules 2019, 24, 1546 7 of 14
2.3. Effect of Mannich Curcuminoids on Inflammatory Mediators
Determination of myeloperoxidase (MPO) enzyme activity provides a measure of neutrophil
infiltration to the inflamed colon [26]. We measured MPO activity from colon tissue homogenate
following TNBS treatment and detected a dramatic increase of activity: 783.5 ± 103.5 vs. abs control
12.6± 1.6 mU/g wet weight (p < 0.001) (Figure 6A) and 131.7± 10 vs. abs control 7.5± 1.3 mU/mg protein
(p < 0.001) (Figure 6B). Tested compounds decreased MPO activity to approximately 50 % of the TNBS
group, suggesting lower infiltration of neutrophils to the inflamed colonic tissue, (C142: 326.7 ± 72.5,
p < 0.01; C150: 370.5 ± 73.1, p < 0.01; Infliximab: 374 53.4, p < 0.01 mU/g wet weight (Figure 6A) and
C142: 74.0 ± 17.8, p < 0.05; C150: 81.9 ± 14.7, p < 0.05; Infliximab 58.6 ± 6.9, p < 0.001 mU/mg protein
(Figure 6B).
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Figure 6. Effects of curcumin analogues on total tissue myeloperoxidase (MPO) activity (mU) normalized
to (A) wet weight (grams) of the tissue or (B) protein content (mg) in the sample. MPO enzyme
activity was significantly decreased both by C142 and C150 Mannich curcuminoids. MPO activity was
measured as described in Section 4.6 of Materials and Methods. Results are shown as mean ± S.E.M.;
n = 8–11; * p < 0.05, ** p < 0.01, *** p < 0.001 pair-wise comparison with TNBS-treated group.
NF-κB, a master regulator of inflammatory conditions [27,28], plays a central role in the
development of inflammatory cascade of the pathogenesis of colitis [29,30]. The involvement of
NF-κB and whether Mannich curcuminoids could inhibit NF-κB-driven transcriptional activity have
been investigated in an NF-κB-driven luciferase reporter cell line. Lipopolysaccharide (LPS), a cell
wall component of Gram-negative bacteria, the canonical ligand of TLR4 (Toll-like receptor 4) receptor,
has been reported to rapidly activate NF-κB [31]. LPS stimulation caused a five-fold induction of
the reporter construct, while co-treatment with Mannich curcuminoids inhibited NF-κB activity in a
concentration-dependent manner (Figure 7A,B). Co-treatment of LPS with C142 or C150, resulted in
3.57 µM or 1.6 µM EC50 values, respectively.
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NF-κB activation in a concentration-dependent manner, as described in Section 4.7 of Materials and
Methods. Luminescence (counts per seconds (cps)) is proportional to NF-κB-driven transcriptional
activity. Results are shown as mean± S.E.M.; *** p < 0.001 pair-wise comparison with LPS-treated group.
During the pro-inflammatory response of colitis among others, NF-κB drives the expression
of TNF-α and IL-6 [32,33]. Since TNF-α is a key factor in the acute phase response, its blocking by
neutralizing antibodies reached a breakthrough in the management of colitis [34]. Similarly, IL-6 is
also a therapeutic target in the clinical management of colitis [35]. Since our curcuminoids were able to
inhibit NF-κB induced transcriptional activity we speculated that the expression of its downstream
targets would also be inhibited. Another cytokine, IL-4 could be induced by LPS and could play a
pro-inflammatory role in the intestinal microenvironment [36,37]. Therefore TNF-α, IL-6, and IL-4 gene
expression was investigated in LPS-stimulated human peripheral blood mononuclear cells (PBMCs).
Interestingly, qRT-PCR (quantitative real-time polymerase chain reaction) data revealed that only
C150 exerted a profound inhibition of the expression of TNF-α (p < 0.001), IL-6 (p < 0.001), and IL-4
(p < 0.001) upon LPS stimulus (Figure 8).
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3. Discussion
The incidence of inflammatory bowel disease (IBD) increases gradually in western countries
and, despite the emerging field of anti-inflammatory drug development, there is a high need for
novel therapeutics. Over the last few decades, several studies reported the therapeutic effect
of naturally-occurring curcu in in c litis via scavenging f e radic ls, supporting a tioxidant ,
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inhibiting NF-κB, and myeloperoxidase activity, suppressing the production of inflammatory
cytokines/chemokines (TNF-α, IL-6, interferon-γ, C-C motif chemokine ligand 17, chemokine (C-X-C
motif) ligand 15) [38–40]. Since curcumin is a hydrophobic polyphenol with reduced solubility
and stability in water-based solvents, which results in inefficient bowel absorption, low serum
concentration, and consequently limited biological availability [41–43], it is necessary to design and
synthetize curcumin analogs to increase bioavailability and potency [15,20–22].
Mannich curcuminoids, synthetized in our laboratory (Figure 1B), were tested for
anti-inflammatory activity in a rat model of TNBS-induced colitis. The appearance of haemorrhagic
and necrotic lesions was obvious after the 72 h induction of colitis in the 8 cm long standard colonic
preparation under investigation (Figure 2B). Both C142 and C150 reduced the macroscopically-visible
tissue destruction (Figure 2C,D) and the inflammatory conditions of the submucosal layers (Figure 3C,D).
Treatment with C142 or C150 rescued the loss of body weight (Figure 4A) and C150 decreased the
weight of standard colon preparations proportional to 20% less tissue oedema (Figure 4B). C142 and
C150 curcumin analogues caused 25% decrease in the severity of colonic inflammation (Figure 5A)
and haemorrhagic lesion size (Figure 5B). We investigated NF-κB activity, the master regulator of the
development of inflammation. Lipopolysaccharide co-treatment with Mannich curcuminoids inhibited
NF-κB activity in a concentration-dependent manner in an NF-κB-driven luciferase expressing reporter
cell line (Figure 7). We also investigated the anti-inflammatory effect of Mannich curcuminoids on the
activity of NF-κB target MPO and on the expression of NF-κB target cytokines TNF-α and IL-6 [44].
Colonic MPO enzyme activity used as a measure of intense neutrophil infiltration was 50% decreased
by both C142 and C150 Mannich curcuminoids (Figure 6). C150 exerted a profound inhibition of
the expression of cytokines: TNF-α, IL-6, and IL-4 in human PBMCs upon LPS stimulus (Figure 8).
Mannich curcuminoids reported herein executed a powerful anti-inflammatory activity that provides
the basis for further studies related to curcumin and curcumin analogues to treat colitis.
4. Materials and Methods
4.1. Animals
Adult male Wistar rats (180–220 g) were kept in small groups. The animals had access to standard
laboratory chow (Bioplan Ltd., Hungary) and drinking water ad libitum throughout the experiments.
Rats were housed in a Minimal Disease animal house with controlled temperature (23 ◦C) and a
light/dark (12 h:12 h) cycle. Before induction of colitis, food was withdrawn overnight and rats were
placed in clean cages. The animal care and research protocols were in accordance with the national and
international guidelines, reviewed and approved by the Regional Animal Health Authority, Csongrad
County, in possession of an ethical clearance XX./592/2018.
4.2. Experimental Design
Animals were divided into five groups randomly: 1, absolute control (vehicle treated
non-colitis-induced, n = 8); 2, TNBS (vehicle treated colitis-induced, n = 10); 3, positive control
(Infliximab treated colitis-induced, n = 10); 4, C142 curcumin analogue challenged (C142 treated
colitis-induced, n = 10); and 5, C150 curcumin analogue challenged (C150 treated colitis-induced,
n = 11). Before the beginning of the experimental period, rats were allowed to acclimate to the cages for
a week, after that, colitis was induced by 2,4,6-trinitrobenzenesulphonic acid (TNBS, Sigma-Aldrich)
once 10 mg was dissolved in 0.25 mL of 50 % (w/v) ethanol. The intracolonic administration of TNBS
was performed with an 8 cm long plastic catheter under transient ether anesthesia, as described by
Morris et al. [45]. Rats were weighed three times a week until the induction of colitis and following
TNBS challenge, daily. Animals were sacrificed 72 h after the induction of colitis. The distal 8-cm long
section of the colon was dissected, longitudinally opened, gently rinsed with ice-cold physiological
saline, photographed (Panasonic lumix DMC-TZ6, digital camera, Kadoma, Japan) or the determination
Molecules 2019, 24, 1546 10 of 14
of macroscopic colonic inflammatory damage. The colon was weighed and divided for histology and
into longitudinal segments to be used for the biochemical analyses.
4.3. Dosage and Treatment
Each treatment started after colitis induction as soon as possible and was performed twice a day
(at 9 am and 5 pm) during the experiment. Both curcumin analogues C142 and C150 (Avidin Ltd.,
Hungary) were administered orally in 40 mg/kg dosage. Common vehicle of curcumin analogues
consists of 80% Peg-200 (Sigma-Aldrich, St. Louis., MO, USA) and 20% Chremophor EL (BASF,
Ludwigshafen, Germany) dissolved in water for injection in 1:10 final ratio. The anti-TNF-α chimeric
monoclonal antibody, Infliximab (Remicade, 100 mg, Schering-Plough, Kenilworth, NJ, USA), was
administered once daily, intravenously in a 3 mg/kg dosage. Absolute and TNBS controls were treated
with the vehicle of curcumin analogues orally. In order to treat the cells in culture curcumin analogues:
C142 and C150 were dissolved at 10 mM in DMSO (Sigma-Aldrich) and further diluted in RPMI cell
culture media (Thermo Fisher Scientific, Waltham, MA, USA).
4.4. Haematoxylin and Eosin Staining
Tissue samples for histology were taken 2–3 cm from the anus and fixed in 4% formaldehyde at
4 ◦C overnight. Tissue was placed into histology cassettes and dehydrated through graded ethanol to
xylene and embedded in paraffin in a Leica TP1020 (Wetzlar, Germany) tissue processor. Sections were
cut transversely at 5 µm thickness and processed for standard haematoxylin and eosin staining with
Leica ST5010 Autostainer. Following staining, the tissue was mounted using a permanent mounting
medium (CV Ultra, Leica). Sections were observed and photographed with a Zeiss Axio Imager.Z2
light microscope equipped with a Digital Microscopy Camera AxioCam ICc 5 (Oberkochen, Germany).
4.5. Damage Score and Lesion Measurement
The degree of colonic inflammation and ulceration was scored on a 0–11 scale in a randomized,
blinded fashion adapted from Boughton-Smith et al. [25]. The criteria have been determined as
described previously: 0 = no damage, 1 = focal hyperemia without ulcers, 2 = ulceration without
hyperemia or bowel wall thickening, 3 = ulceration with inflammation at 1 site, 4 = more than 2 sites of
ulceration and inflammation, 5 = more than 2 major sites of ulceration and inflammation or 1 site of
ulceration/inflammation extending >1 cm along the length of the colon, 6–11 = the score is increased
by 1 for each additional centimeter of involvement [24].
The extent of macroscopically-apparent inflammation, ulceration, and tissue disruption was
determined in a randomized manner from the color images using proprietary computerized planimetry
Java plugin (Stat_2_1_1, developed in our laboratory [7]) for ImageJ 1.0 (National Institutes of Health,
the Laboratory for Optical and Computational Instrumentation (University of Wisconsin, Wisconsin,
WI, USA). The area of macroscopically-visible mucosal involvement was calculated and expressed as
the percentage of the total colonic segment area under investigation.
4.6. Measurement of Myeloperoxidase Activity
To measure myeloperoxidase activity we used a modified method described by Bradley et al. [46].
The 8 cm longitudinal strips of the colon were weighed, homogenized freshly (Ultra-turrax T25
IKA-Labortechnik, Staufen, Germany, 12,000 g, twice for 30 s; 250 mg colon/mL buffer) in ice-cold
phosphate buffer (50 mM, pH 6.0), containing 0.5% CTAB (hexadecyltrimethylammonium bromide,
Sigma-Aldrich), freeze-thawed three times in liquid nitrogen and then centrifuged at 10.000 g for
15 min at 4 ◦C. A 12 µL aliquot of the supernatant was then mixed with a 280 µL phosphate buffer
(50 mM, pH 6.0), supplemented with 0.167 mg/mL O-adenosine dihydrochloride (Sigma-Aldrich), and
the reaction was started with 10 µl 0.03% hydrogen peroxide, then assayed spectrophotometrically at
490 nm after 90 s shaking (Benchmark Microplate reader, Bio-Rad Labs, Hercules, CA, USA). MPO
activity was expressed as mU/g wet weight tissue or mU/mg protein. A standard curve was created
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using serial dilution of peroxidase (Sigma-Aldrich). According to Bradley et al., one unit of the
peroxidase activity was defined as that degrading one µmole of peroxide per minute at 25 ◦C [46].
In order to measure the protein concentration aliquots (20 µL) of the diluted protein, samples
were mixed with 980 µL of distilled water. Bradford reagents (Sigma-Aldrich) (200 µL) were added
to each sample and mixed vigorously. Following 10 min incubation, the samples were assayed
spectrophotometrically at 595 nm. Protein level was expressed as mg protein/mL.
4.7. NF-κB Inhibition Assay
Mouse B16 melanoma cell line was purchased from the American Type Culture Collection
(ATCC, Manassas, WV, USA) and was cultured in RPMI medium supplemented with 10% Fetal Calf
Serum (FCS, Thermo Fisher Scientific). NF-κB reporter B16 cell line was created by transfection with
the pNF-κB-Luc/neo reporter construct with the FuGene reagent (Promega, Madison, Wisconsin,
USA). Stable transfected cell lines were selected by Neomycin (G418, Sigma-Aldrich) treatment.
B16/NF-κB-Luc cells (7 × 104 cells/well) were grown on 96 well luminoplates (Corning Life Sciences,
Corning, NY, USA). After overnight incubation, when cells reached confluency, cell culture medium
was changed and cells were pre-treated with a serial dilution of C142 and C150 curcumin analogs (or
vehicle control) for 30 min before induction of NF-κB by lipopolysaccharide (LPS, Escherichia coli
O111:B4, 500 ng/mL, Sigma-Aldrich). After 6 h of incubation the cell culture medium was removed and
the cells were washed with phosphate-buffered saline (PBS) and lysed for 10 min at room temperature
in Luciferase Cell Culture Lysis Reagent (20 µL/well, Promega). Substrate (luciferine) was added
(20 µL/well, Bright-Glo™ Luciferase Assay System, Promega) and luciferase activity (counts per
seconds (cps)) was measured in a microplate reader (Victor, Perkin Elmer, Waltham, MA, USA). NF-κB
inhibition was calculated with relation to vehicle control cells from nine parallel measurements for all
treatment conditions. The half-maximal effective concentration (EC50) was determined in relation to
only LPS-treated wells in GraphPad Prism (version 5.01, La Jolla, CA, USA).
4.8. Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR)
Human peripheral blood mononuclear cells (PBMC) were isolated from healthy volunteers by
Ficoll density gradient centrifugation. Briefly, the withdrawal of 20 mL blood was carried out by a nurse
into EDTA Vacutainer (Becton Dickinson, Franklin Lakes, NJ, USA). Twenty mL phosphate-buffered
saline (PBS) was added to the blood under a safety laminar hood (Euroclone, Pero, MI, Italy). Leucosep
tubes (Greiner Bio-One, Kremsmünster, Austria) were loaded with 20 mL diluted blood and centrifuged
at 800 g for 20 min. After the removal of the plasma, the ring of PBMCs were collected into 15 mL
conical tubes (Corning Life Sciences) and washed with 10 mL PBS at 500 g for 5 min two times. Cells
were suspended in RPMI 10% FCS cell culture media and counted in a Bürker-chamber with trypan
blue (Sigma-Aldrich). PBMCs (3 × 106) were plated in 6 well tissue culture dishes (Corning Life
Sciences) in RPMI 10% FCS. Cells were treated in 2 mL total volume with test compounds C142 and
C150 at 2.5 µM or LPS at 100 ng/mL for 4 h.
After treatment, nucleic acid preparation was done by using the RNA purification kit
(Direct-zolTM RNA MiniPrep Kit, Zymo Research, Irvine, CA, USA), according to an already published
protocol [47]. The quality and quantity of the isolated RNA were measured with NanoDrop1000
Version 3.8.1. (Thermo Fisher Scientific). Reverse transcription from 600 ng of total RNA was
performed with the High Capacity cDNA Archive Kit (Applied Biosystems, Foster, CA, USA) in
a total volume of 30 µL according to the manufacturer’s protocol. Quantitative real-time PCR
(qRT-PCR) was performed on the LightCycler® 96 System (Roche, Basel, Switzerland), using
gene-specific primers with SYBR Green protocol, as described previously [48]. Briefly, for cycling,
each 10 µL PCR reaction contained 1 µL cDNA (20 ng), 250 nM primers, and 5 µL qPCRBIO
SyGreen Mix Lo-ROX (2X, PCR Byosystems, London, UK). Primer sequences and accession numbers
were as follows: IL6 (NM_000600.4; NM_001318095.1, F: 5’-GACCCAACCACAAATGCCAG-3’,
R: 5’-GTGCCCATGCTACATTTGCC-3’); TNF (NM_000594.3, F: 5’-CACAGTGAAGTGCTGGCAAC-3’,
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R: 5’-GATCAAAGCTGTAGGCCCCA-3’); IL4 (NM_000589.4, NM_172348.2, NM_001354990.1) F: 5’-
CCACGGACACAAGTGCGATA-3’, R: 5’- CTTCTGCTCTGTGAGGCTGTT-3’); ACTB (NM_001101,
F: 5’-CCAACCGCGAGAAGATGA-3’, R: 5’-CCAACCGCGAGAAGATGA-3’. The PCR protocol was
as follows: Enzyme activation at 95 ◦C for 2 min, 45 cycles of denaturation at 95 ◦C for 10 s, annealing
at 60 ◦C, and extension at 60 ◦C for 10 s. All the qPCRs were performed with three replicates.
After amplification, the melting curve was checked to verify the specificity of the PCR reactions. The Ct
values were normalized to ACTB gene for each time point. The presented relative gene expression
ratios were ∆∆CT values (log2). All values were presented as mean ± standard error of the mean
(S.E.M.).
4.9. Data Representation and Statistical Analysis
Results are shown as mean ± S.E.M.; statistical comparisons were performed by two-tailed
Student’s t-test as pairwise comparisons as described in the figure legends. In all statistical comparisons,
probability “p” was set as the level of significance (set at * p < 0.05, ** p < 0.01, ***, p < 0.001). Data
were processed and analyzed using Microsoft Excel (Microsoft Office 2016, Redmond, WA, USA), and
visualized using GraphPad Prism.
Author Contributions: Conceptualization, C.V. and L.G.P.; methodology, L.I.N, G.J.S., A.B., L.Z.F., and A.P.;
formal analysis, L.H. and L.G.P.; investigation, G.J.S., L.I.N., A.B., L.Z.F., A.H., M.B., and B.K.; resources, C.V.
and L.G.P.; data curation, G.J.S., L.I.N., C.V., and L.G.P.; writing—original draft preparation G.J.S., L.I.N., J.A.B.,
L.H., I.K., and L.G.P.; writing—review and editing, G.J.S, L.I.N., L.H., and L.G.P.; visualization, G.J.S. and L.I.N.;
supervision, C.V. and L.G.P.; project administration C.V. and L.G.P.; funding acquisition C.V. and L.G.P.
Funding: This research was supported by the following grants: 2018-1.3.1-VKE-2018-00018, GINOP-2.3.2-15
-2016-00030 and GINOP-2.3.2-15-2016-00001 by the National Research, Development and Innovation Office.
The Ministry of Human Capacities, Hungary grant 20391-3/2018/FEKUSTRAT is acknowledged. Gábor J. Szebeni
was supported by the UNKP-18-4 New National Excellence Program of the Ministry of Human Capacities
(UNKP-18-4-SZTE-73) and János Bolyai by the Research Scholarship of the Hungarian Academy of Sciences
(BO/00139/17/8).
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Chen, L.; Deng, H.; Cui, H.; Fang, J.; Zuo, Z.; Deng, J.; Li, Y.; Wang, X.; Zhao, L. Inflammatory responses and
inflammation-associated diseases in organs. Oncotarget 2018, 9, 7204–7218. [CrossRef] [PubMed]
2. Hunter, P. The inflammation theory of disease. The growing realization that chronic inflammation is crucial
in many diseases opens new avenues for treatment. EMBO Rep. 2012, 13, 968–970. [CrossRef] [PubMed]
3. Szebeni, G.J.; Vizler, C.; Kitajka, K.; Puskas, L.G. Inflammation and cancer: Extra- and intracellular
determinants of tumor-associated macrophages as tumor promoters. Med. Inflamm. 2017, 2017, 9294018.
[CrossRef] [PubMed]
4. Szebeni, G.J.; Vizler, C.; Nagy, L.I.; Kitajka, K.; Puskas, L.G. Pro-tumoral inflammatory myeloid cells as
emerging therapeutic targets. Int. J. Mol. Sci. 2016, 17, 1958. [CrossRef]
5. Bernstein, C.N.; Fried, M.; Krabshuis, J.H.; Cohen, H.; Eliakim, R.; Fedail, S.; Gearry, R.; Goh, K.L.; Hamid, S.;
Khan, A.G.; et al. World gastroenterology organization practice guidelines for the diagnosis and management
of ibd in 2010. Inflamm. Bowel. Dis. 2010, 16, 112–124. [CrossRef]
6. Molodecky, N.A.; Soon, I.S.; Rabi, D.M.; Ghali, W.A.; Ferris, M.; Chernoff, G.; Benchimol, E.I.; Panaccione, R.;
Ghosh, S.; Barkema, H.W.; et al. Increasing incidence and prevalence of the inflammatory bowel diseases
with time, based on systematic review. Gastroenterology 2012, 142, 46–54. [CrossRef]
7. Szalai, Z.; Szasz, A.; Nagy, I.; Puskas, L.G.; Kupai, K.; Kiraly, A.; Berko, A.M.; Posa, A.; Strifler, G.; Barath, Z.;
et al. Anti-inflammatory effect of recreational exercise in tnbs-induced colitis in rats: Role of nos/ho/mpo
system. Oxid. Med. Cell Longev. 2014, 2014, 925981. [CrossRef]
8. Talapka, P.; Nagy, L.I.; Pal, A.; Poles, M.Z.; Berko, A.; Bagyanszki, M.; Puskas, L.G.; Fekete, E.; Bodi, N.
Alleviated mucosal and neuronal damage in a rat model of crohn’s disease. World J. Gastroenterol. 2014,
20, 16690–16697. [CrossRef]
Molecules 2019, 24, 1546 13 of 14
9. Talapka, P.; Berko, A.; Nagy, L.I.; Chandrakumar, L.; Bagyanszki, M.; Puskas, L.G.; Fekete, E.; Bodi, N.
Structural and molecular features of intestinal strictures in rats with crohn’s-like disease. World J. Gastroenterol.
2016, 22, 5154–5164. [CrossRef]
10. Ford, A.C.; Moayyedi, P.; Hanauer, S.B. Ulcerative colitis. BMJ 2013, 346, f432. [CrossRef]
11. Meier, J.; Sturm, A. Current treatment of ulcerative colitis. World J. Gastroenterol. 2011, 17, 3204–3212.
[PubMed]
12. Ordas, I.; Eckmann, L.; Talamini, M.; Baumgart, D.C.; Sandborn, W.J. Ulcerative colitis. Lancet 2012,
380, 1606–1619. [CrossRef]
13. Basnet, P.; Skalko-Basnet, N. Curcumin: An anti-inflammatory molecule from a curry spice on the path to
cancer treatment. Molecules 2011, 16, 4567–4598. [CrossRef] [PubMed]
14. Hewlings, S.J.; Kalman, D.S. Curcumin: A review of its’ effects on human health. Foods 2017, 6, 92. [CrossRef]
[PubMed]
15. Szebeni, G.J.; Balazs, A.; Madarasz, I.; Pocz, G.; Ayaydin, F.; Kanizsai, I.; Fajka-Boja, R.; Alfoldi, R.;
Hackler, L., Jr.; Puskas, L.G. Achiral mannich-base curcumin analogs induce unfolded protein response and
mitochondrial membrane depolarization in panc-1 cells. Int. J. Mol. Sci. 2017, 18, 2105. [CrossRef] [PubMed]
16. Cheng, A.L.; Hsu, C.H.; Lin, J.K.; Hsu, M.M.; Ho, Y.F.; Shen, T.S.; Ko, J.Y.; Lin, J.T.; Lin, B.R.; Ming-Shiang, W.;
et al. Phase i clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant
lesions. Anticancer Res. 2001, 21, 2895–2900.
17. Lao, C.D.; Ruffin, M.T.t.; Normolle, D.; Heath, D.D.; Murray, S.I.; Bailey, J.M.; Boggs, M.E.; Crowell, J.;
Rock, C.L.; Brenner, D.E. Dose escalation of a curcuminoid formulation. BMC Complement. Altern. Med. 2006,
6, 10. [CrossRef] [PubMed]
18. Gupta, S.C.; Patchva, S.; Aggarwal, B.B. Therapeutic roles of curcumin: Lessons learned from clinical trials.
AAPS J. 2013, 15, 195–218. [CrossRef]
19. Liu, W.; Zhai, Y.; Heng, X.; Che, F.Y.; Chen, W.; Sun, D.; Zhai, G. Oral bioavailability of curcumin: Problems
and advancements. J. Drug Target 2016, 24, 694–702. [CrossRef]
20. Gyuris, M.; Hackler, L., Jr.; Nagy, L.I.; Alfoldi, R.; Redei, E.; Marton, A.; Vellai, T.; Farago, N.; Ozsvari, B.;
Hetenyi, A.; et al. Mannich curcuminoids as potent anticancer agents. Arch. Pharm. (Weinheim) 2017,
350, e1700005. [CrossRef]
21. Nagy, L.I.; Feher, L.Z.; Szebeni, G.J.; Gyuris, M.; Sipos, P.; Alfoldi, R.; Ozsvari, B.; Hackler, L., Jr.; Balazs, A.;
Batar, P.; et al. Curcumin and its analogue induce apoptosis in leukemia cells and have additive effects with
bortezomib in cellular and xenograft models. Biomed. Res. Int. 2015, 2015, 968981. [CrossRef] [PubMed]
22. Hackler, L., Jr.; Ozsvari, B.; Gyuris, M.; Sipos, P.; Fabian, G.; Molnar, E.; Marton, A.; Farago, N.; Mihaly, J.;
Nagy, L.I. The curcumin analog c-150, influencing nf-kappab, upr and akt/notch pathways has potent
anticancer activity in vitro and in vivo. PLoS ONE 2016, 11, e0149832. [CrossRef] [PubMed]
23. Mao, H.; Wan, J.; Pan, Y. Facile and diastereoselective synthesis of β-acetamido ketones and keto esters via
direct mannich-type reaction. Tetrahedron 2009, 65, 1026–1032. [CrossRef]
24. Horvath, K.; Varga, C.; Berko, A.; Posa, A.; Laszlo, F.; Whittle, B.J. The involvement of heme oxygenase-1
activity in the therapeutic actions of 5-aminosalicylic acid in rat colitis. Eur. J. Pharmacol. 2008, 581, 315–323.
[CrossRef] [PubMed]
25. Boughton-Smith, N.K.; Wallace, J.L.; Whittle, B.J. Relationship between arachidonic acid metabolism,
myeloperoxidase activity and leukocyte infiltration in a rat model of inflammatory bowel disease. Agents Act.
1988, 25, 115–123. [CrossRef]
26. Khan, A.A.; Alsahli, M.A.; Rahmani, A.H. Myeloperoxidase as an active disease biomarker: Recent
biochemical and pathological perspectives. Med. Sci. 2018, 6, 33. [CrossRef] [PubMed]
27. Zhang, Q.; Lenardo, M.J.; Baltimore, D. 30 years of nf-kappa b: A blossoming of relevance to human
pathobiology. Cell 2017, 168, 37–57. [CrossRef] [PubMed]
28. Vlahopoulos, S.A. Aberrant control of nf-kappab in cancer permits transcriptional and phenotypic plasticity,
to curtail dependence on host tissue: Molecular mode. Cancer Biol. Med. 2017, 14, 254–270. [PubMed]
29. Andresen, L.; Jorgensen, V.L.; Perner, A.; Hansen, A.; Eugen-Olsen, J.; Rask-Madsen, J. Activation of nuclear
factor kappab in colonic mucosa from patients with collagenous and ulcerative colitis. Gut 2005, 54, 503–509.
[CrossRef]
30. Atreya, I.; Atreya, R.; Neurath, M.F. Nf-kappab in inflammatory bowel disease. J. Intern. Med. 2008,
263, 591–596. [CrossRef]
Molecules 2019, 24, 1546 14 of 14
31. Wang, X.Y.; Quinn, P.J. Endotoxins: Lipopolysaccharides of gram-negative bacteria. Endotoxins 2010, 53, 3–25.
32. Deree, J.; Martins, J.O.; Melbostad, H.; Loomis, W.H.; Coimbra, R. Insights into the regulation of tnf-alpha
production in human mononuclear cells: The effects of non-specific phosphodiesterase inhibition. Clinics
2008, 63, 321–328. [CrossRef] [PubMed]
33. Libermann, T.A.; Baltimore, D. Activation of interleukin-6 gene expression through the nf-kappa b
transcription factor. Mol. Cell. Biol. 1990, 10, 2327–2334. [CrossRef] [PubMed]
34. Levin, A.D.; Wildenberg, M.E.; van den Brink, G.R. Mechanism of action of anti-tnf therapy in inflammatory
bowel disease. J. Crohns. Colitis 2016, 10, 989–997. [CrossRef] [PubMed]
35. Parisinos, C.A.; Serghiou, S.; Katsoulis, M.; George, M.J.; Patel, R.S.; Hemingway, H.; Hingorani, A.D.
Variation in interleukin 6 receptor gene associates with risk of crohn’s disease and ulcerative colitis.
Gastroenterology 2018, 155, 303–306 e302. [CrossRef]
36. Mukherjee, S.; Chen, L.Y.; Papadimos, T.J.; Huang, S.; Zuraw, B.L.; Pan, Z.K. Lipopolysaccharide-driven
th2 cytokine production in macrophages is regulated by both myd88 and tram. J. Biol. Chem. 2009,
284, 29391–29398. [CrossRef] [PubMed]
37. Van Kampen, C.; Gauldie, J.; Collins, S.M. Proinflammatory properties of il-4 in the intestinal
microenvironment. Am. J. Physiol. Gastrointest. Liver Physiol. 2005, 288, G111–G117. [CrossRef]
38. Toden, S.; Theiss, A.L.; Wang, X.; Goel, A. Essential turmeric oils enhance anti-inflammatory efficacy of
curcumin in dextran sulfate sodium-induced colitis. Sci. Rep. 2017, 7, 814. [CrossRef] [PubMed]
39. Baliga, M.S.; Joseph, N.; Venkataranganna, M.V.; Saxena, A.; Ponemone, V.; Fayad, R. Curcumin, an
active component of turmeric in the prevention and treatment of ulcerative colitis: Preclinical and clinical
observations. Food Funct. 2012, 3, 1109–1117. [CrossRef]
40. Jian, Y.T.; Mai, G.F.; Wang, J.D.; Zhang, Y.L.; Luo, R.C.; Fang, Y.X. Preventive and therapeutic effects of
nf-kappab inhibitor curcumin in rats colitis induced by trinitrobenzene sulfonic acid. World J. Gastroenterol.
2005, 11, 1747–1752. [CrossRef]
41. Wang, Y.J.; Pan, M.H.; Cheng, A.L.; Lin, L.I.; Ho, Y.S.; Hsieh, C.Y.; Lin, J.K. Stability of curcumin in buffer
solutions and characterization of its degradation products. J. Pharm. Biomed. Anal. 1997, 15, 1867–1876.
[CrossRef]
42. Mondal, S.; Ghosh, S.; Moulik, S.P. Stability of curcumin in different solvent and solution media: Uv-visible
and steady-state fluorescence spectral study. J. Photochem. Photobiol. B 2016, 158, 212–218. [CrossRef]
[PubMed]
43. Rego-Filho, F.G.; de Araujo, M.T.; de Oliveira, K.T.; Bagnato, V.S. Validation of photodynamic action via
photobleaching of a new curcumin-based composite with enhanced water solubility. J. Fluoresc. 2014,
24, 1407–1413. [CrossRef] [PubMed]
44. Yang, Y.; Wu, J.; Wang, J.K. A database and functional annotation of nf-kappa b target genes. Int. J. Clin.
Exp. Med. 2016, 9, 7986–7995.
45. Morris, G.P.; Beck, P.L.; Herridge, M.S.; Depew, W.T.; Szewczuk, M.R.; Wallace, J.L. Hapten-induced model
of chronic inflammation and ulceration in the rat colon. Gastroenterology 1989, 96, 795–803. [CrossRef]
46. Bradley, P.P.; Priebat, D.A.; Christensen, R.D.; Rothstein, G. Measurement of cutaneous inflammation:
Estimation of neutrophil content with an enzyme marker. J. Investig. Dermatol. 1982, 78, 206–209. [CrossRef]
47. Szebeni, G.J.; Balog, J.A.; Demjen, A.; Alfoldi, R.; Vegi, V.L.; Feher, L.Z.; Man, I.; Kotogany, E.; Guban, B.;
Batar, P.; et al. Imidazo[1,2-b]pyrazole-7-carboxamides induce apoptosis in human leukemia cells at
nanomolar concentrations. Molecules 2018, 23, 2845. [CrossRef]
48. Szebeni, G.J.; Tancos, Z.; Feher, L.Z.; Alfoldi, R.; Kobolak, J.; Dinnyes, A.; Puskas, L.G. Real architecture for
3d tissue (raft) culture system improves viability and maintains insulin and glucagon production of mouse
pancreatic islet cells. Cytotechnology 2017, 69, 359–369. [CrossRef]
Sample Availability: Samples of the compounds are available via contacting the corresponding author
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
